FMP
Jounce Therapeutics, Inc.
JNCE
NASDAQ
Inactive Equity
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
1.88 USD
0 (0%)
About
ceo
Ms. Kimberlee Cobleigh Drapkin C.P.A., CPA
sector
Healthcare
industry
Biotechnology
website
https://jouncetx.com
exchange
NASDAQ
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics...
CIK
0001640455
ISIN
US4811161011
CUSIP
481116101
Address
780 Memorial Drive
Phone
857 259 3840
Country
US
Employee
141
IPO Date
Jan 26, 2017
Summary
CIK
0001640455
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
481116101
ISIN
US4811161011
Country
US
Price
1.88
Beta
0.75
Volume Avg.
3.47M
Market Cap
98.95M
Shares
-
52-Week
0.5773-5.37
DCF
2.92
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.96
P/B
-
Website
https://jouncetx.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest JNCE News
It looks like there's no news available.
